146 related articles for article (PubMed ID: 15994934)
1. The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo.
Osthus RC; Karim B; Prescott JE; Smith BD; McDevitt M; Huso DL; Dang CV
Cancer Res; 2005 Jul; 65(13):5620-7. PubMed ID: 15994934
[TBL] [Abstract][Full Text] [Related]
2. JPO1/CDCA7, a novel transcription factor E2F1-induced protein, possesses intrinsic transcriptional regulator activity.
Goto Y; Hayashi R; Muramatsu T; Ogawa H; Eguchi I; Oshida Y; Ohtani K; Yoshida K
Biochim Biophys Acta; 2006; 1759(1-2):60-8. PubMed ID: 16580749
[TBL] [Abstract][Full Text] [Related]
3. A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation.
Prescott JE; Osthus RC; Lee LA; Lewis BC; Shim H; Barrett JF; Guo Q; Hawkins AL; Griffin CA; Dang CV
J Biol Chem; 2001 Dec; 276(51):48276-84. PubMed ID: 11598121
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells.
Huang A; Ho CS; Ponzielli R; Barsyte-Lovejoy D; Bouffet E; Picard D; Hawkins CE; Penn LZ
Cancer Res; 2005 Jul; 65(13):5607-19. PubMed ID: 15994933
[TBL] [Abstract][Full Text] [Related]
5. The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation.
Gill RM; Gabor TV; Couzens AL; Scheid MP
Mol Cell Biol; 2013 Feb; 33(3):498-513. PubMed ID: 23166294
[TBL] [Abstract][Full Text] [Related]
6. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.
Conner EA; Lemmer ER; Omori M; Wirth PJ; Factor VM; Thorgeirsson SS
Oncogene; 2000 Oct; 19(44):5054-62. PubMed ID: 11042693
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
8. Reactive oxygen species regulate nucleostemin oligomerization and protein degradation.
Huang M; Whang P; Chodaparambil JV; Pollyea DA; Kusler B; Xu L; Felsher DW; Mitchell BS
J Biol Chem; 2011 Apr; 286(13):11035-46. PubMed ID: 21242306
[TBL] [Abstract][Full Text] [Related]
9. Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis.
Schmidt T; Karsunky H; Gau E; Zevnik B; Elsässer HP; Möröy T
Oncogene; 1998 Nov; 17(20):2661-7. PubMed ID: 9840930
[TBL] [Abstract][Full Text] [Related]
10. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc.
Haupt Y; Harris AW; Adams JM
Oncogene; 1992 May; 7(5):981-6. PubMed ID: 1570158
[TBL] [Abstract][Full Text] [Related]
11. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.
Lawlor ER; Soucek L; Brown-Swigart L; Shchors K; Bialucha CU; Evan GI
Cancer Res; 2006 May; 66(9):4591-601. PubMed ID: 16651409
[TBL] [Abstract][Full Text] [Related]
12. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
[TBL] [Abstract][Full Text] [Related]
13. Transgenic mice for Cre-inducible overexpression of the oncogenes c-MYC and Pim-1 in multiple tissues.
Roh M; Kim J; Song C; Wills M; Abdulkadir SA
Genesis; 2006 Oct; 44(10):447-53. PubMed ID: 17013838
[TBL] [Abstract][Full Text] [Related]
14. A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas.
Largaespada DA; Kaehler DA; Mishak H; Weissinger E; Potter M; Mushinski JF; Risser R
Oncogene; 1992 Apr; 7(4):811-9. PubMed ID: 1565479
[TBL] [Abstract][Full Text] [Related]
15. MYC fails to efficiently shape malignant transformation in T-cell acute lymphoblastic leukemia.
Loosveld M; Bonnet M; Gon S; Montpellier B; Quilichini B; Navarro JM; Crouzet T; Goujart MA; Chasson L; Morgado E; Picard C; Hernandez L; Fossat C; Gabert J; Michel G; Nadel B; Payet-Bornet D
Genes Chromosomes Cancer; 2014 Jan; 53(1):52-66. PubMed ID: 24249258
[TBL] [Abstract][Full Text] [Related]
16. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
[TBL] [Abstract][Full Text] [Related]
17. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis.
Barsyte-Lovejoy D; Lau SK; Boutros PC; Khosravi F; Jurisica I; Andrulis IL; Tsao MS; Penn LZ
Cancer Res; 2006 May; 66(10):5330-7. PubMed ID: 16707459
[TBL] [Abstract][Full Text] [Related]
18. Activation of the nuclear oncogenes N-myc and c-jun in carcinoid [correction of cartinoid] tumors of transgenic mice carrying the human adenovirus type 12 E1 region gene.
Sagara M; Sugiyama F; Horiguchi H; Kamma H; Ogata T; Yagami K; Murakami K; Fukamizu A
DNA Cell Biol; 1995 Feb; 14(2):95-101. PubMed ID: 7865136
[TBL] [Abstract][Full Text] [Related]
19. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice.
Terradillos O; Billet O; Renard CA; Levy R; Molina T; Briand P; Buendia MA
Oncogene; 1997 Jan; 14(4):395-404. PubMed ID: 9053836
[TBL] [Abstract][Full Text] [Related]
20. C-myc expression in cell lines derived from chronic myeloid leukemia.
Gómez-Casares MT; Vaqué JP; Lemes A; Molero T; Delgado MD; León J
Haematologica; 2004 Feb; 89(2):241-3. PubMed ID: 15003904
[No Abstract] [Full Text] [Related]
[Next] [New Search]
